Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+, Mozilla Firefox 20+, Internet Explorer 11, Opera 15–18, Apple Safari 7, SeaMonkey 2.15-2.23

Become a member
  1. OncologyPRO
  2. Meeting Resources
  3. ESMO Virtual Congress 2020

Boehringer Ingelheim - Focus on NSCLC treatment options

Treatments After Progression in the First-Line of Non-Mutated NSCLC Adenocarcinoma

Date

14 Sep 2020

Session

Boehringer Ingelheim - Focus on NSCLC treatment options

Presenters

Silvia Novello

Authors

S. Novello

Author affiliations

  • Oncology Dept., Università Degli Studi Di Torino - Orbassano, 10043 - Orbassano/IT

Resources

Login to get immediate access to this content.

If you do not have an ESMO account, please create one for free.

Login

Resources from the same session

Welcome and introduction

Presenter: Tanja Cufer

Session: Boehringer Ingelheim - Focus on NSCLC treatment options

Resources:

Webcast

Uncommon EGFR mutations

Presenter: Xiuning Le

Session: Boehringer Ingelheim - Focus on NSCLC treatment options

Resources:

Webcast

The Future of NSCLC

Presenter: Melissa Johnson

Session: Boehringer Ingelheim - Focus on NSCLC treatment options

Resources:

Webcast

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings

  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.